Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,004 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer.
Park YH, Im SA, Park K, Wen J, Lee KH, Choi YL, Lee WC, Min A, Bonato V, Park S, Ram S, Lee DW, Kim JY, Lee SK, Lee WW, Lee J, Kim M, Kim HS, Weinrich SL, Ryu HS, Kim TY, Dann S, Kim YJ, Fernandez DR, Koh J, Wang S, Park SY, Deng S, Powell E, Ravi RK, Bienkowska J, Rejto PA, Park WY, Kan Z. Park YH, et al. Among authors: park s, park sy, park k, park wy. Genome Med. 2023 Jul 20;15(1):55. doi: 10.1186/s13073-023-01201-7. Genome Med. 2023. PMID: 37475004 Free PMC article.
Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study.
Kim SH, Jung KH, Kim TY, Im SA, Choi IS, Chae YS, Baek SK, Kang SY, Park S, Park IH, Lee KS, Choi YJ, Lee S, Sohn JH, Park YH, Im YH, Ahn JH, Kim SB, Kim JH. Kim SH, et al. Among authors: park ih, park yh, park s. Cancer Res Treat. 2016 Oct;48(4):1373-1381. doi: 10.4143/crt.2015.475. Epub 2016 Mar 23. Cancer Res Treat. 2016. PMID: 27034147 Free PMC article.
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.
Park YH, Lee KH, Sohn JH, Lee KS, Jung KH, Kim JH, Lee KH, Ahn JS, Kim TY, Kim GM, Park IH, Kim SB, Kim SH, Han HS, Im YH, Ahn JH, Kim JY, Kang J, Im SA. Park YH, et al. Among authors: park ih. Int J Cancer. 2018 Dec 15;143(12):3240-3247. doi: 10.1002/ijc.31651. Epub 2018 Nov 7. Int J Cancer. 2018. PMID: 29978467 Free article. Clinical Trial.
Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
Kim HK, Lee SH, Kim YJ, Park SE, Lee HS, Lim SW, Cho JH, Kim JY, Ahn JS, Im YH, Yu JH, Park YH. Kim HK, et al. Among authors: park yh, park se. BMC Cancer. 2019 Jan 17;19(1):84. doi: 10.1186/s12885-018-5258-9. BMC Cancer. 2019. PMID: 30654765 Free PMC article.
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.
Kim JY, Lee E, Park K, Jung HH, Park WY, Lee KH, Sohn J, Lee KS, Jung KH, Kim JH, Lee KH, Im SA, Park YH. Kim JY, et al. Among authors: park yh, park k, park wy. Int J Cancer. 2019 Sep 15;145(6):1669-1678. doi: 10.1002/ijc.32188. Epub 2019 Feb 27. Int J Cancer. 2019. PMID: 30720867 Free article. Clinical Trial.
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).
Kim JY, Lee E, Park K, Im SA, Sohn J, Lee KS, Chae YS, Kim JH, Kim TY, Jung KH, Park YH; Breast Cancer Committee of the Korean Cancer Study Group. Kim JY, et al. Among authors: park yh, park k. Breast Cancer Res Treat. 2019 Nov;178(2):367-377. doi: 10.1007/s10549-019-05400-y. Epub 2019 Aug 12. Breast Cancer Res Treat. 2019. PMID: 31407230
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators. Modi S, et al. Among authors: park yh. N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11. N Engl J Med. 2020. PMID: 31825192 Free PMC article. Clinical Trial.
Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. Among authors: park yh. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549. N Engl J Med. 2020. PMID: 32101663 Clinical Trial.
3,004 results